

Application No. 10/509,633
Amendment Dated 12/22/2005
Reply to Office Action of 12/13/2005

Remarks/Arguments:

The specification has been amended to correct an error in the priority claim. A Supplemental Application Data Sheet (ADS) is enclosed correcting the same error. Applicants note the USPTO records are correct so no petition is necessary. Applicants have also amended the representative details on the ADS following the recent transfer of this case back to AstraZeneca for prosecution.

Further to the telephone calls between Examiner Grazier and the undersigned on 19th and 20th December 2005, Applicants are filing herein an amended set of claims in response to the restriction requirement dated 13th December 2005. As agreed with the Examiner the amendments do not correspond exactly to the Groups I-X outlined in the Office Action.

As agreed with the Examiner, **Applicants hereby elect Claims 7 and 10-21 outlined above in response to the restriction requirement.**

Specifically Applicants have:

- Cancelled Claims 1-6.
- Amended Claim 7 by importing the definitions of the variable groups from Claim 1 so that the reference to Claim 1 could be removed. Claim 7 has then been restricted by making R³ cyano (the formula (I) has been re-drawn) and removing 'a group of Formula (II)' from the definition of R⁴. This resulted in the deletion of both disclaimers.
- Cancelled Claims 8-9.
- Amended Claim 10 to remove the compound which no longer fell within the scope of Claim 7.
- Amended the dependency of Claim 11 to include all the compound claims.
- Amended Claim 12 to correct the dependency and delete the process which is no longer appropriate. The structures have also been redrawn to reflect the change in the structure in Claim 7.
- Added Claims 13 - 21. Basis for Claim 13 is to be found at paragraphs 258-260; Claim 14 at 261-263; Claims 15 and 16 at 238; Claim 17 at 240; Claim 18 at 242; Claim 19 at 244; and Claims 20 and 21 at 245 of the published US patent application.

Applicants submit no new matter has been added by the amendments outlined above.

Application No. 10/509,633
Amendment Dated 12/22/2005
Reply to Office Action of 12/13/2005

The Examiner also asked, for the purposes of searching, for an election of an exact definition within each of the substituents. For this purpose we elect:

- R¹ is C₁₋₄alkoxy (specifically methoxy);
- X is —S—;
- R² is hydrogen;
- R⁴ is carbamoyl;
- R⁵ is C₁₋₄alkyl (specifically methyl);
- p is 0; and
- q is 3.

Applicants also elect Example 18 as the single compound.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested

The Commissioner is hereby authorized to charge \$150 for excess claim fees. Please charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100467-1P US.

Respectfully submitted,



Name: Lucy Padgett
Dated: December 22, 2005
Reg. No.: L0074
Phone No.: 781-839-4182

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451

Enclosed Supplemental ADS
Annotated ADS.